Equities

Axim Biotechnologies Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AXIM:PKC

Axim Biotechnologies Inc

Actions
  • Price (USD)0.0145
  • Today's Change0.003 / 22.67%
  • Shares traded330.65k
  • 1 Year change+360.32%
  • Beta-0.6289
Data delayed at least 15 minutes, as of Feb 06 2026 20:16 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Axim Biotechnologies, Inc. develops and commercializes rapid, point-of-care diagnostic tests focused on ocular and systemic health. The Company's TearScan platform enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings, enhancing diagnostic confidence and treatment outcomes. The Company's product portfolio falls under the Eye Health sector and consists of the two FDA cleared 510(k) tests for dry eye disease (DED) and allergic conjunctivitis, both testing tears for these diseases. It has also internally developed an immunoassay for a potential third product which would measure MMP-9 in tears. MMP-9 is a biomarker for ocular surface inflammation and is an additional diagnostic tool for DED and other eye diseases. Its ophthalmological diagnostic tests include Ocular Immunoglobulin E (IgE) Test and Lactoferrin Test. IgE is a biomarker for allergic conjunctivitis, which often mimics dry eye disease or co-exists with dry eye disease.

  • Revenue in USD (TTM)92.90k
  • Net income in USD-4.14m
  • Incorporated2010
  • Employees6.00
  • Location
    Axim Biotechnologies Inc6191 Cornerstone Court, E, Suite 114SAN DIEGO 92121United StatesUSA
  • Phone+1 (212) 751-0001
  • Fax+1 (775) 786-6755
  • Websitehttps://aximbiotech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Catheter Precision Inc730.00k-22.19m3.15m22.00--0.459--4.32-37.38-37.380.93714.120.0281.646.3533,181.82-66.93-128.03-78.29-160.1292.60-242.70-2,393.84-15,268.880.4569-66.840.0449---4.98-19.8969.45---24.21--
ENvue Medical Inc2.69m-5.21m3.18m15.00--0.0695--1.18-83.93-83.937.4642.000.09090.83646.45179,000.00-25.01-97.63-32.90-149.1830.0253.04-275.12-397.830.6675--0.0669--12.0537.000.1617------
Encision Inc6.30m-380.94k3.19m22.00--1.71--0.5061-0.0284-0.02840.50570.11051.662.277.98286,353.60-10.05-3.17-14.19-4.4052.6451.47-6.05-2.010.9127-5.690.1094---0.464-3.0968.17--8.09--
Vycor Medical Inc1.90m-338.88k3.67m7.00------1.93-0.0103-0.01030.0548-0.12061.891.576.73271,678.60-1.44-36.90----85.3589.43-0.7625-26.120.10280.8609----8.812.67-11.32---40.90--
bioAffinity Technologies Inc6.78m-14.74m3.83m57.00--0.3314--0.5651-20.74-20.749.342.570.7489161.377.97118,890.20-162.88---222.52--27.86---217.50--3.64-2.690.0332--269.68---13.89------
Reflect Scientific Inc1.72m-29.42k3.99m7.00--1.9221.352.32-0.0004-0.00040.02010.02430.68260.84298.78245,945.70-1.1711.10-1.3213.2158.4762.48-1.7110.009.46--0.00---47.09-6.99-613.46------
Nuwellis Inc8.17m-16.56m4.40m38.00--0.9116--0.539-107.66-107.6626.642.871.111.656.71214,947.40-225.22-87.78-390.32-108.5359.0757.73-202.83-195.831.42-1.050.00---1.409.6653.05---34.30--
Co-Diagnostics Inc507.90k-32.18m4.73m132.00--0.0939--9.31-29.44-29.440.455124.820.00870.28444.343,847.73-54.95-1.67-59.80-1.7834.0382.14-6,336.17-3.713.51--0.00---42.5378.68-6.53--45.89--
Axim Biotechnologies Inc92.90k-4.14m4.83m6.00------51.97-0.0163-0.01630.0003-0.03240.0233----15,483.33-103.73-154.34---390.7316.94---4,451.97-36,362.71---3.14----345.05-27.38-29.10------
Profusa Inc0.00-39.09m5.39m0.00---------3.72-3.720.00-0.81380.00-------599.88-----------------14.56---------849.77------
Dalrada Financial Corp18.37m-23.89m5.77m0.00------0.314-0.2172-0.21720.1626-0.13030.90894.865.34---118.42-100.15-1,575.08-1,511.4525.5728.94-130.29-92.980.2685-6.36----2.3276.7114.86--15.56--
Kelyniam Global Inc-100.00bn-100.00bn6.19m0.00--8.41----------0.0146------------------------0.6993--0.3831--------------
Innovative Eyewear Inc2.39m-7.85m6.21m11.00--0.5891--2.59-2.63-2.630.73691.970.21011.4529.13217,504.50-68.92-143.06-73.91-176.8022.844.06-327.98-574.8910.13--0.00--41.99220.75-16.55------
STRATA Skin Sciences Inc30.98m-11.04m6.30m106.00--4.29--0.2034-2.62-2.627.290.24940.87364.517.80292,264.20-31.13-14.64-52.77-21.5157.7659.75-35.64-21.510.746-4.020.921--0.61161.226.87---10.13--
ADM Tronics Unlimited Inc3.36m-129.58k6.41m7.00--7.2818.221.91-0.0019-0.00190.04970.0131.474.956.60---5.67-17.71-10.33-27.7539.0740.78-3.86-19.080.8633-3.740.3461--7.81-1.7285.97------
Data as of Feb 06 2026. Currency figures normalised to Axim Biotechnologies Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.